Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCH 900800
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SCH 900800 is an investigational drug that has been studied in clinical trials for Parkinson's disease, specifically to assess its pharmacokinetics when administered as oral tablets in L-DOPA-treated subjects. The precise mechanism of action, chemical structure, and broader pharmacological profile are not detailed in the available sources. The drug appears to be under development for neurological disorders such as Parkinson's disease. **Developer:** Merck
Beyond the preview
Go deeper on SCH 900800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCH 900800.